Current Opinion in Lipidology

Papers
(The TQCC of Current Opinion in Lipidology is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Regulation of lipoprotein lipase-mediated lipolysis of triglycerides67
Remnant lipoproteins: are they equal to or more atherogenic than LDL?56
Genetic, biochemical, and clinical features of LCAT deficiency: update for 202037
Mendelian randomization as a tool for causal inference in human nutrition and metabolism34
ANGPTL3 as therapeutic target34
Apolipoprotein C-II: the re-emergence of a forgotten factor34
CD36 (SR-B2) as master regulator of cellular fatty acid homeostasis32
Very long-chain saturated fatty acids and diabetes and cardiovascular disease31
Hypertriglyceridemia: new approaches in management and treatment28
The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?28
Impact of ultra-processed food consumption on metabolic health27
Update on apolipoprotein B26
Lipids and peripheral neuropathy24
Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia22
Fibroblasts in atherosclerosis: heterogeneous and plastic participants21
Advances, gaps and opportunities in the detection of familial hypercholesterolemia: overview of current and future screening and detection methods21
Management of familial hypercholesterolemia in pregnancy21
Transport of LDLs into the arterial wall: impact in atherosclerosis19
Lipids and brain inflammation in APOE4-associated dementia18
The impact of race and ethnicity on lipoprotein(a) levels and cardiovascular risk18
Small dense low-density lipoprotein particles: clinically relevant?18
Extracellular matrix: paving the way to the newest trends in atherosclerosis18
Update on cerebrotendinous xanthomatosis17
Characteristics of plaque lipid-associated macrophages and their possible roles in the pathogenesis of atherosclerosis17
The clinical applicability of polygenic risk scores for LDL-cholesterol: considerations, current evidence and future perspectives17
Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease17
Depression and cardiovascular disease17
Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees17
Measurement of carotid plaque burden16
Lipoprotein(a): is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality?16
Evidence for improved survival with treatment of homozygous familial hypercholesterolemia16
Vascular stiffening and endothelial dysfunction in atherosclerosis15
Dietary treatment to lower cholesterol and triglyceride and reduce cardiovascular risk15
Familial combined hyperlipidemia is a polygenic trait15
Targeting epigenetics as atherosclerosis treatment: an updated view15
The expanding role of lyso-phosphatidylcholine acyltransferase-3 (LPCAT3), a phospholipid remodeling enzyme, in health and disease14
Lipid effects of glucagon-like peptide 1 receptor analogs14
Metabolic and cardiovascular outcomes of bariatric surgery14
Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies13
Homozygous familial hypercholesterolemia: what treatments are on the horizon?13
The iterative lipid impact on inflammation in atherosclerosis13
Apolipoprotein F: a natural inhibitor of cholesteryl ester transfer protein and a key regulator of lipoprotein metabolism13
Omega-3 fatty acids and cognitive function13
Understanding the ins and outs of lipoprotein (a) metabolism12
Polygenic scores for dyslipidemia: the emerging genomic model of plasma lipoprotein trait inheritance11
Sphingosine-1-phosphate: metabolism, transport, atheroprotection and effect of statin treatment11
Epigenetics of paraoxonases11
The interconnection between lipoprotein(a), lipoprotein(a) cholesterol and true LDL-cholesterol in the diagnosis of familial hypercholesterolemia11
HDL and persistent inflammation immunosuppression and catabolism syndrome11
Atherosclerosis: cell biology and lipoproteins11
Age-associated arterial calcification: the current pursuit of aggravating and mitigating factors11
Familial hypercholesterolemia: is it time to separate monogenic from polygenic familial hypercholesterolemia?11
The need for polygenic score reporting standards in evidence-based practice: lipid genetics use case10
Polygenic risk scores: how much do they add?10
How should low-density lipoprotein cholesterol be calculated in 2022?10
Nonalcohol fatty liver disease: balancing supply and utilization of triglycerides10
Cardiovascular risk in patients with nonalcoholic fatty liver disease: looking at the liver to shield the heart10
Dyslipidemia and aortic valve disease10
Angiopoietin-like proteins and postprandial partitioning of fatty acids10
Recent advances in ABCG5 and ABCG8 variants10
0.022277116775513